Synageva BioPharma Corp

Synageva BioPharma — Merger or Acquisition (May 2015)

30 slides from Synageva BioPharma's merger presentation, May 11, 2015

  1. Slide 1: Global Town Hall

    Global Town Hall David Hallal Chief Executive Officer, Alexion May 11, 2015 Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a - 12 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commiss

  2. Slide 2: Alexion key highlights

    2 • Exclusive focus on life - transforming therapies for patients with devastating, life - threatening disorders • Continued steady growth of Soliris ® ( eculizumab ) in both PNH and aHUS across geographies worldwide • Preparing for 2015 launch of next product, Strensiq for the treatment of patients

  3. Slide 3: Fast Facts: Who We Are

    3 Fast Facts: Who We Are • Global, fully integrated biopharmaceutical company • Serving patients with devastating and rare diseases • Established in 1992 • First product approval in 2007 (Soliris® for PNH) • More than 2,500 employees worldwide • Platform to serve patients in 50 countries • U.S. publ

  4. Slide 4: Global locations

    4 Sydney, Australia Asia - Pacific Regional HQ Country Operations Mumbai , India Global Business Services Shanghai, China Country Operations Tokyo, Japan Japan Regional HQ Country Operations Toronto, Canada Country Operations Cambridge, MA Translational Medicine Group Cheshire, CT Global Headquarter

  5. Slide 5: Revenue and non-GAAP EPS growth

    5 * $2,1465M excludes ~$88M in prior years’ sales in France ; ‡ Midpoint of guidance range Growth in PNH and aHUS markets drives increasing operating and financial leverage * $4.84 excludes $0.37/sh in non - GAAP EPS related to ~$88M in prior years’ sales in France ; ‡ Midpoint of guidance range † E

  6. Slide 6: Next Generation Portfolio

    6 Soliris ( eculizumab ) Anti - C5 Antibody PRECLINICAL EARLY CLINICAL DEVELOPMENT ADVANCED CLINICAL DEVELOPMENT REGISTRATION FILINGS Refractory Myasthenia Gravis (MG) Antibody - Mediated Rejection (AMR) Delayed Graft Function (DGF) ALXN1210 METABOLIC DISORDERS INFLAMMATORY DISORDERS GI - GVHD ALXN1

  7. Slide 7: Soliris in PNH and aHUS: Life-Transforming Impact for Patients

    Soliris in PNH and aHUS Life - Transforming Impact for Patients 7

  8. Slide 8: What is PNH?

    8 What is PNH? PNH is an acquired and ultra - rare genetic complement inhibitor deficiency disorder affecting blood cells • Defined by presence of hemolysis (destruction of RBCs by uncontrolled complement activation ) • Patients suffer progressive disease burden, vital organ failure and/or thrombosi

  9. Slide 9: Strensiq regulatory status and launch preparation

    9 9 9 » Deploying field - based medical teams in US, Europe and Japan; hiring our in - country metabolic commercial teams » Leveraging PNH and aHUS learnings to best serve patients with HPP » Initial market research suggests that low disease awareness typically results in missed diagnoses Region Reg

  10. Slide 10: Paroxysmal Nocturnal Hemoglobinuria (PNH)

    10 ▪ Globally, the majority of patients with PNH have yet to commence appropriate therapy ▪ Significant opportunity to increase penetration across geographies including the U.S., Europe and Japan as well as more recently launched territories ▪ Disease awareness and diagnostic initiatives continue to

  11. Slide 11: What is aHUS?

    11 What is aHUS? aHUS is a genetic, ultra - rare complement inhibitor deficiency disorder affecting children & adults • Leads to clotting in small blood vessels throughout the body (systemic TMA) • Causes progressive & sudden damage to vital organs, resulting in stroke, heart attack and renal failur

  12. Slide 12: aHUS Market Opportunity is Larger than PNH

    12 12 Atypical Hemolytic Uremic Syndrome (aHUS) Market Opportunity is Larger than PNH In the U.S. 14 quarters post approval, there are more patients with aHUS actively receiving Soliris ▪ Matched for time since their respective approvals, more patients in the U.S. are currently receiving Soliris for

  13. Slide 13: Beyond PNH & aHUS

    Beyond PNH & aHUS Growing Our Portfolio with New Soliris Indications and Other Highly Innovative Products 13

  14. Slide 14: Strensiq in hypophosphatasia

    14 Genetic and often life - threatening ultra - rare metabolic disease Caused by mutations in the gene for tissue non - specific alkaline phosphatase (TNSALP) Accumulation of metabolic substrates results in the following: • Prevention of effective bone formation, leading to bone destruction and defo

  15. Slide 15: 15

    15

  16. Slide 16: Alexion: Global Leader in Rare Diseases

    16 Alexion: Global Leader in Rare Diseases • Kanuma ( sebelipase alfa) for LAL Deficiency aligns with our exclusive focus on bringing transformative therapies to patients suffering from under - diagnosed , devastating and rare diseases, such as PNH, aHUS and HPP Exclusive Focus on Life - Transformin

  17. Slide 17: Synageva BioPharma: Ideal Strategic and Operational Fit

    17 Synageva BioPharma: Ideal Strategic and Operational Fit • Patient - centric culture • Focus on discovering, developing and delivering medicines for patients with rare and devastating diseases Exclusive Focus on Rare Diseases • Kanuma under review for the treatment of patients with LAL Deficiency

  18. Slide 18: Synageva's Pipeline will Strengthen and Broaden Alexion's Portfolio

    18 Synageva’s Pipeline will Strengthen and Broaden Alexion’s Clinical and Preclinical Portfolio Source: Synageva Investor Presentation, April 2015 • Pipeline of rare disease assets • Highly innovative late - stage product, Kanuma (sebelipase alfa) • Expression platform to develop novel and next gene

  19. Slide 19: LAL-D is an Ideal Fit for Alexion's Focus

    19 LAL - D is an Ideal Fit for Alexion’s Exclusive Focus on Treating Patients with Devastating and Rare Diseases Sources: Hillmen P, Lewis SM, Bessler M et al. N Engl J Med. 1995; 333:1253 - 1258; Caprioli, J., et al. Blood. 2006; 108:1267 - 12 79; Whyte et al. Poster presented at the 2014 PAS Meeti

  20. Slide 20: Kanuma Aligned with Alexion's Portfolio

    20 Kanuma, an Investigational Treatment for LAL - D, is Aligned with Alexion’s Portfolio of Life - Transforming Therapies Sources: Hill A et al. Presented at the Annual ASH Meeting December, 2012; Johnson et al. Presented at ERA - EDTA Congress , May, 2014; Licht C et al. ASH 2012. Poster 985; Whyte

  21. Slide 21: Alexion's Track Record Identifying Patients

    21 Alexion’s Proven Track Record in Identifying Patients with Underdiagnosed, Devastating and Rare Diseases PNH Annual Newly Identified PNH Patients in Core Markets Alexion’s PNH diagnostic initiatives have enabled the company to identify a similar number of new PNH patients annually since the Solir

  22. Slide 22: Diagnostic Expertise Leveraged for HPP and LAL-D

    22 Alexion’s PNH and aHUS Diagnostic Expertise will be Leveraged for Our HPP and LAL - D Patient Identification Initiatives PNH aHUS HPP LAL - D Driving Diagnosis Across Multiple Rare Diseases Soliris for PNH Soliris for aHUS Hematology & Nephrology Franchise Strensiq for HPP Kanuma for LAL - D Meta

  23. Slide 23: Alexion to Maximize Synageva's Value

    23 Alexion to Maximize Synageva’s Value, Leveraging Our Expertise Across Our 50 - Country Platform • Leverage our 50 - country platform and expand Alexion’s metabolic franchise to launch Kanuma • Utilize Alexion’s global regulatory expertise to secure approvals in all key markets • Secure worldwide

  24. Slide 24: Kanuma will Further Accelerate and Diversify Revenues

    24 Following Approval, Kanuma w ill Further Accelerate and Diversify Our Strong, Consistently Growing Revenues Across Our 50 - Country Platform Revenues in 2016 – 2020 are illustrative and should not be taken as guidance * $2,1465M excludes ~$88M in prior years’ sales in France ; ‡ Midpoint of FY15

  25. Slide 25: Metabolic Franchise: Anticipated Launches in 2015

    25 METABOLIC FRANCHISE Anticipated Launches in 2015 PRECLINICAL CLINICAL DEVELOPMENT REGISTRATION FILINGS Alexion Program Synageva Program cPMP MoCD Type A Strensiq HPP Asfotase Alfa NF - 1 SBC - 105 GACI/Other Undisclosed Preclinical #6 SBC - 103 MPSIIIB mRNA Therapies #1 Kanuma LAL - D Undisclosed

  26. Slide 26: Creating the Most Robust Rare Disease Pipeline in Biotech

    26 Creating the Most Robust Rare Disease Pipeline in Biotech PRECLINICAL EARLY CLINICAL DEVELOPMENT ADVANCED CLINICAL DEVELOPMENT REGISTRATION FILINGS MARKETED Soliris Next Gen Inflammatory Metabolic Undisclosed Synageva Complement Inhibition Soliris DGF ALXN1007 APS Complement Inhibitor (4) ALXN550

  27. Slide 27: Our Combined Ambitions for Tomorrow

    Our Combined Ambitions for Tomorrow • Global leader in developing, manufacturing and commercializing the most innovative portfolio of complement inhibitors • Multiple therapeutic areas independent of complement • Most innovative R&D in biotech industry • World - class capability in manufacturing the

  28. Slide 28: Alexion and Synageva – a Shared Culture

    Alexion and Synageva – a Shared Culture • Setting the highest patient - centric ambitions • Never settling for conventional plans and timelines • Self - critical discipline • Insatiable thirst for doing better • Turning “No” into “Yes”

  29. Slide 29: Questions

    Questions ACeExion (Synageya) BioPharma

  30. Slide 30: Forward-Looking Statements

    Forward - Looking Statements This communication includes statements that may be forward - looking statements. The words “believe,” “expect,” “anticipate,” “pr oject” and similar expressions, among others, generally identify forward - looking statements. Alexion and Synageva caution that these forwar

Synageva Biopharma — Merger or Acquisition (May 2015) on 6ix